The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Journal of Clinical Oncology 2026

View at publisher
Authors: N. Hunter, Heather A. Parsons, Leslie Cope, J. V. Canzoniero, Fabio C.P. Navarro, Sherif El-Refai, Jesus D. Anampa, Joseph A. Sparano, Mothaffar F. Rimawi, A. Storniolo, Candace Mainor, Rita Nanda
+24 more A. DeMichele, Gaorav P. Gupta, E Stringer-Reasor, F. Lynce, Erin F. Cobain, Shannon Puhalla, R. C. Jankowitz, Brent N. Rexer, I. Mayer, E. Shelley Hwang, Kimberly Blackwell, Walid El Ayass, Young Lee, Carol Tweed, Mary Wilkinson, Angela Pennisi, Bonnie Sun, Pamela A. Wright, Julie R. Gralow, Richard Chen, S. M. Boyle, Vered Stearns, Antonio C. Wolff, Ben Ho Park
DOI: 10.1200/jco-25-02934
Cited by: 12
References: 20

Abstract

PURPOSE Patients with stage II/III human epidermal growth factor receptor 2 (HER2)–positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification. METHODS Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (

Fields of Study & Subjects

Cancer Genomics and Diagnostics Cancer Cells and Metastasis Breast Cancer Treatment Studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
14
Pages
1283–1295
Publication date
10 March 2026
Language
EN